^
    Back
    Association details:
    Biomarker:CD38 expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Sarclisa (isatuximab-irfc) (CD38 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

    Published date:
    09/02/2021
    Excerpt:
    In the disseminated CD38+, T-ALL, and B-ALL xenograft models, isatuximab is able to induce robust antitumor activity, even at low doses. This study shows that isatuximab has significant in vitro and in vivo activity against ALL cells with robust ADCC and ADCP effects that are associated with CD38 expression levels in both T-ALL and B-ALL.
    DOI:
    10.1158/1535-7163.MCT-21-0058